The NK-CD11c+ axis and the IL-6 pathway may be promising new targets for host-directed therapies aimed at reducing the severity of immune pathology, which drives morbidity and mortality in those infected by tuberculosis (TB).The study demonstrates for the first time that NK-CD11c+ cell interactions increase IL-6-mediated inflammation and reduce survival in T2DM mice infected with Mtb. The NK-CD11c+ cell axis appears to be a promising new target for reducing inflammation and mortality in tuberculosis patients with type 2 diabetes. Here, IL6 is linked to type 2 diabetes mellitus.